ASX ANNOUNCEMENT

100+ Pharmacies in Liverpool UK Launch FebriDx® Service

Melbourne, VIC. (12 January 2022) - Lumos Diagnostics (ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the NHS Liverpool Clinical Commissioning Group (CCG) and Community Pharmacy Liverpool have launched a new clinical service at more than 100 pharmacies that includes the 10-minute FebriDx® test to differentiate bacterial from viral respiratory infection.

"Adoption of FebriDx in the front-line pharmacy setting is a strategically important milestone for its commercialization across healthcare," said **Rob Sambursky, MD, president and CEO of Lumos Diagnostics**. "This provides an effective, real-world model for improving patient care while driving antimicrobial stewardship in outpatient care settings."

The FebriDx test will be used for patients with an acute cough at pharmacies across Liverpool under a new minor ailments service known as **Pharmacy First**, to enable rapid diagnoses and appropriate antibiotic prescribing – without the need for a general practitioner (GP) appointment first.

"Our goal is to provide patients with more convenient access to testing and treatment for acute cough under a new Patient Group Direction (PDG)," explained **Matt Harvey, Chief Officer of Community Pharmacy Liverpool**. "With the high volumes of patients with coughs and respiratory problems during the winter season, we see a real opportunity to bring this test into local pharmacies to help us provide treatment for patients more quickly – without the need for a GP appointment or prescription first."

In addition to the convenience of point-of-care results, clinical studies show that the FebriDx test allows healthcare providers to rule out bacterial infections for their patients with 99% confidence, which can help reduce the unnecessary use of antibiotics and reduce antimicrobial resistance.

FebriDx is manufactured in the U.S. in facilities with ISO 13485 and MDSAP certificates. FebriDx is approved for use by qualified healthcare professionals in the UK, Europe, Canada, Australia and UAE. An application for U.S. regulatory clearance of FebriDx is currently under review by the FDA and on track for a decision during fiscal year 2022.

This announcement has been approved by the Lumos Disclosure Committee.

# # #

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:
Jennifer Christiansen – Global
VP, Corporate Marketing and Communications, Lumos Diagnostics
jennifer.christiansen@lumosdiagnostics.com
+1 920 784 3153

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:
Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598